AllianceBernstein
ANTH

AllianceBernstein’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

AllianceBernstein’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,700
Closed -$9K – 3209
2017
Q1 		$9K Hold
2,700
– – ﹤0.01% 2987
2016
Q4 		$14K Hold
2,700
– – ﹤0.01% 3009
2016
Q3 		$68K Sell
2,700
-488
-15% -$12.3K ﹤0.01% 2949
2016
Q2 		$79K Buy
3,188
+675
+27% +$19.1K ﹤0.01% 2931
2016
Q1 		$73K Sell
2,513
-1,075
-30% -$29.2K ﹤0.01% 2850
2015
Q4 		$133K Hold
3,588
– – ﹤0.01% 2824
2015
Q3 		$175K Buy
3,588
+1,913
+114% +$134K ﹤0.01% 2810
2015
Q2 		$116K Buy
+1,675
New +$77.5K ﹤0.01% 2942

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

AllianceBernstein's ANTH Position: Q2 2017 in Review

AllianceBernstein sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 2,700 shares — an estimated $9K sold.

AllianceBernstein first reported a position in ANTH in Q2 2015 and held it in 8 quarters. The position peaked at $175K in Q3 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

  • AllianceBernstein reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • AllianceBernstein sold 2,700 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $9K.
  • AllianceBernstein first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 8 quarters.
  • AllianceBernstein's Anthera Pharmaceuticals, Inc. position peaked at $175K in Q3 2015.
  • 40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on AllianceBernstein's 13F filing for Q2 2017, filed 10 Aug 2017.